Table 4.
aba-ada exposure |
ama-ana exposure |
|||||||
---|---|---|---|---|---|---|---|---|
factor |
b
|
SE
|
Z
|
p
|
b
|
SE
|
z
|
p
|
(Intercept) | −0.06 | 0.16 | −0.39 | .7 | 0.79 | 0.42 | 1.87 | .061 |
Continuum | −2.64 | 0.32 | −8.26 | <.001 | −2.83 | 0.29 | −9.81 | <.001 |
POA | 0.47 | 0.14 | 3.40 | <.001 | 0.82 | 0.29 | 2.84 | <.005 |
TrialType | 0.5 | 0.41 | 1.20 | .23 | −0.21 | 0.83 | −0.26 | .8 |
Continuum:POA | −0.12 | 0.23 | −0.51 | .61 | −0.26 | 0.27 | −0.96 | .34 |
Continuum:TrialType | −0.51 | 0.20 | −2.47 | <.05 | 1.71 | 0.42 | 4.05 | <.001 |
POA:TrialType | 0.7 | 0.30 | 2.32 | <.05 | 1.15 | 0.37 | 3.07 | <.005 |
Continuum:POA:TrialType | −0.76 | 0.56 | −1.35 | 0.18 | 0.10 | 0.46 | 0.22 | .83 |